Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the fifteen brokerages that are covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $103.62.

ITCI has been the topic of several research analyst reports. Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, January 14th. Needham & Company LLC reaffirmed a "hold" rating and set a $100.00 target price on shares of Intra-Cellular Therapies in a report on Monday, January 13th. Leerink Partnrs cut Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Piper Sandler restated a "neutral" rating and issued a $132.00 target price (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and issued a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd.

Intra-Cellular Therapies Stock Up 0.3 %

Shares of ITCI stock traded up $0.44 during mid-day trading on Friday, hitting $127.56. 1,569,131 shares of the stock were exchanged, compared to its average volume of 4,738,316. The company has a market cap of $13.56 billion, a PE ratio of -146.62 and a beta of 0.72. The firm has a fifty day moving average of $102.37 and a 200 day moving average of $86.66. Intra-Cellular Therapies has a 52-week low of $62.78 and a 52-week high of $128.00.

Insider Buying and Selling at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of the company's stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. This represents a 4.55 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Intra-Cellular Therapies

Large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. boosted its stake in shares of Intra-Cellular Therapies by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company's stock worth $1,878,000 after purchasing an additional 2,157 shares during the last quarter. Barclays PLC lifted its holdings in Intra-Cellular Therapies by 282.0% in the 3rd quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company's stock worth $2,521,000 after buying an additional 25,435 shares in the last quarter. Oak Ridge Investments LLC increased its holdings in Intra-Cellular Therapies by 74.1% during the 4th quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company's stock worth $1,656,000 after purchasing an additional 8,440 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in shares of Intra-Cellular Therapies by 31.9% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 454,538 shares of the biopharmaceutical company's stock worth $33,258,000 after purchasing an additional 109,892 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in Intra-Cellular Therapies by 3.3% in the third quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company's stock worth $43,735,000 after purchasing an additional 18,865 shares during the period. 92.33% of the stock is owned by institutional investors and hedge funds.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.